24/7 Patient Assistance: 760-405-8205

Nasser Hanna, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Lung Cancer Testicular Mesothelioma

specialties & services

  • Bio & Insurance Information

    Dr. Nasser Hanna is a medical oncologist who lives in Indianapolis, Indiana and works with several hospitals including Richard L Roudebush VA Medical Center. He got his medical degree from University of Missouri and did an internship and a residency at University of Iowa. He completed his medical studies with a fellowship at Indiana University Health Methodist Hospital. Dr. Nasser Hanna is board certified in oncology and has over 20 years of experience.



  • Education & Training

    dept_icon

    University Of Missouri--Columbia School Of Medicine Graduated in 1995

    Medical School

    dept_icon

    University Iowa Completed in 1996

    Internship

    dept_icon

    University Iowa Completed in 1998

    Residency

    dept_icon

    Indiana University Health Methodist Hospital

    Fellowship

  • Board Certifications

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    Eskenazi Health

    Languages: English/Spanish

    (317) 880-0000

    720 Eskenazi Ave

    Indianapolis, Indiana 46202

    Read More

    IU Health University Hospital

    Languages: English/Spanish

    (317) 944-5000

    550 University Blvd

    Indianapolis, Indiana 46202

    Read More

    Richard L Roudebush VA Medical Center

    Languages: English/Spanish

    (317) 554-0000

    1481 W 10th St

    Indianapolis, Indiana 46202

    Read More
  • Publications & Memberships

    Dr. Nasser Hanna has contributed to 3 publications.

    Prognostic factors in patients with poor risk germ cell tumors: a retrospective analysis of the Indiana University experience from 1990-2014.

    Adra, N.,Althouse, S. K.,Liu, H.,Brames, M. J.,Hanna, N. H.,Einhorn, L. H.,Albany, C.; Ann. Oncol.. 2016 Feb 11.

    See more >>

    Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier C.

    Adra, N.,Albany, C.,Brames, M. J.,Case-Eads, S.,Johnson, C. S.,Liu, Z.,Fausel, C. A.,Breen, T.,Hanna, N. H.,Hauke, R. J.,Picus, J.,Einhorn, L. H.; Support Care Cancer. 2016 Feb 04.

    See more >>

    Electronic nicotine delivery systems: a policy statement from the american association for cancer research and the american society of clinical oncology.

    Brandon, T. H.,Goniewicz, M. L.,Hanna, N. H.,Hatsukami, D. K.,Herbst, R. S.,Hobin, J. A.,Ostroff, J. S.,Shields, P. G.,Toll, B. A.,Tyne, C. A.,Viswanath, K.,Warren, G. W.; J. Clin. Oncol.. 2015 Jan 13.

    See more >>

    Memberships

    American Society of Clinical Oncology